ON Helix 2017 Conference

Dr Marek Tyl Written by Dr Marek Tyl
Published on 04 April 2017
2 min. read

Date: 13 July 2017
Location: Wellcome Genome Campus Conference Centre, Hinxton

Translational research is now at the forefront of most researchers minds. It has never been more crucial for R&D companies and for the benefit of society, to shorten the time to market for new drug and healthcare technologies.

ON Helix, brought to you by One Nucleus is a translational research conference for everyone in the life science sector.

ON Helix is a one day event aimed at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).

It presents the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business:

  • Session 1: Choosing the Right Business Model
  • Session 2: New Technologies in Translational Medicine
  • Session 3: Do Charities Make the Best Investors? 


ON Helix 2017 Conference Keynote Speakers:

Sharon Vosmek, CEO, Astia

David Tapolczay, CEO, MRC Technology

Sara-Jane Dunn, Microsoft

Click to view the 2017 programme for ON Helix.

The conference will commence with a Welcome Reception and Summer BioNewsRound Award on 12 July, more information can be found here.

Please click here to view the delegate rates and here for more information on exhibiting at ON Helix.

To register, please click here.


Full Price Delegate Rate £425 see a full list of delegate fees here.

For further details visit On Helix website www.onhelix.com   

Follow ON Helix on Twitter @OneNucleus  using #onhelix17


Share content

Leave a Reply

In order to comment you need to be part of Inno-Forum. If you’re already a member Log in or Register

We use cookies to ensure that we give you the best tailored experience on our website based on your preferences. By continuing to use our services, you are giving us your consent to use cookies. Learn more here.